UK Medicines Information
Zynbryta (daclizumab): risk minimisation materials
Information type:
Safety alerts
Source:
electronic Medicines compendium
Specialities:
Liver disorders
Summary
A hepatic risk management information leaflet has been produced by the manufacturers to assist physicians in the management of transaminase elevation and potential serious hepatic injury in patients receiving daclizumab.
UKMi comment
A treatment acknowledgment form and patient alert card have been produced in conjunction.
Related links:
Patient card
Acknowledgement form